Otsuka Holdings Co., Ltd. OTSKF
72.00 USD -1.16 (-1.58%)
At closeOct 30, 2026, 4:00 PM EDT
72.00 Day range 72.00
54.26 52-week range 79.00
- YTD
- +32.69%
- 1 year
- +25.52%
- Market cap
- 37.72B
- EPS (ttm)
- 4.65
- P/E ratio
- 15.48
- YTD return
- +32.69%
- 1-year return
- +25.52%
- Volume
- 41
- Avg volume
- 14
- Open
- 72.00
- Previous close
- 73.16
- Day's range
- 72.00 – 72.00
- 52-week range
- 54.26 – 79.00
- Earnings date
- Nov 4, 2026
YTD +18.89 (+34.81%)
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 1.13.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 1.13 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 1.01 | 1.37 | +0.36 | +35.64% |
| Apr 28, 2026 | Mar 31, 2026 | 0.858 | 1.17 | +0.31 | +36.36% |
| Feb 12, 2026 | Dec 31, 2025 | 0.4771 | 0.793 | +0.32 | +66.21% |
| Oct 31, 2025 | Sep 30, 2025 | 1.05 | 1.59 | +0.54 | +51.43% |
| Jul 31, 2025 | Jun 30, 2025 | 1.04 | 1.16 | +0.12 | +11.54% |
News
Aristotle International Equity ADR WM Q1 2026 Contributors And Detractors 
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript 
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript 
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment 
Otsuka (OTCMKTS:OTSKF) Trading Up 3% – Should You Buy? 
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle 
US FDA approves Otsuka's kidney disease drug 
Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript
Your note
Sign in to keep a note on OTSKF — it syncs with the Stock Master app.